Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hemiplegic migraine (HM) is a rare variety of migraine with aura characterized by the presence of a motor weakness during the aura. Hemiplegic migraine has two main forms depending on the familial history: patients with at least one first- or second-degree relative who has aura including motor weakness have familial hemiplegic migraine (FHM); patients without such familial history have sporadic hemiplegic migraine (SHM).
Biomarker and diagnostic research for familial or sporadic hemiplegic migraine has been reported in the published literature.
No approved treatments are currently available for familial or sporadic hemiplegic migraine. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for familial or sporadic hemiplegic migraine, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for familial or sporadic hemiplegic migraine. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: 1-5 in 10,000 (Uncommon).
No clinical trials have been registered for familial or sporadic hemiplegic migraine.
299 publications have been identified in PubMed for familial or sporadic hemiplegic migraine. Kisho has analyzed 170 by research type. Research spans Epidemiology / Natural History (35%), Other (22%), and Review / Meta-Analysis (21%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 59 | 35% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 9:47 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
flunarizine | flunarizine | Xenon Pharmaceuticals, Inc. | 2016 | — | Designated |
Gene therapy approaches for familial or sporadic hemiplegic migraine have been reported in the published literature.
View trials for familial or sporadic hemiplegic migraine
Other research |
37 |
22% |
Research summaries | 36 | 21% |
Clinical study results | 13 | 8% |
Patient case studies | 11 | 6% |
Laboratory research | 10 | 6% |
Testing and diagnosis research | 3 | 2% |
New treatment approaches | 1 | 1% |
Du Y (2026). [PMID: 41422957](https://pubmed.ncbi.nlm.nih.gov/41422957/). *J Affect Disord*. [Epidemiology / Natural History]
Lu W (2026). [PMID: 41748585](https://pubmed.ncbi.nlm.nih.gov/41748585/). *Nat Commun*. [Other]
Butler AE (2026). [PMID: 40298884](https://pubmed.ncbi.nlm.nih.gov/40298884/). *Journal of child health care : for professionals working with children in the hospital and community*. [Review / Meta-Analysis]
Conway KP (2026). [PMID: 40794882](https://pubmed.ncbi.nlm.nih.gov/40794882/). *Nicotine Tob Res*. [Other]
Hemminki K (2026). [PMID: 42113346](https://pubmed.ncbi.nlm.nih.gov/42113346/). *Fam Cancer*. [Epidemiology / Natural History]
Chen G (2026). [PMID: 41289740](https://pubmed.ncbi.nlm.nih.gov/41289740/). *Patient education and counseling*. [Review / Meta-Analysis]
Khabou B (2026). [PMID: 40818735](https://pubmed.ncbi.nlm.nih.gov/40818735/). *Clin Chim Acta*. [Case Report / Case Series]
Florentin A (2026). [PMID: 42049655](https://pubmed.ncbi.nlm.nih.gov/42049655/). *Rech Soins Infirm*. [Other]
Lee SW (2026). [PMID: 42227735](https://pubmed.ncbi.nlm.nih.gov/42227735/). *Fam Process*. [Other]
Hotz JF (2026). [PMID: 41589756](https://pubmed.ncbi.nlm.nih.gov/41589756/). *European journal of neurology*. [Case Report / Case Series]
AI-curated news mentioning familial or sporadic hemiplegic migraine
Updated Sep 15, 2026
Recent research delves into the genetics and pathophysiology of hemiplegic migraine, providing insights that could inform future therapeutic strategies. Understanding these mechanisms may enhance treatment options for affected patients.